Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Blood cancer journal - 7 Mar 2018

Tefferi Ayalew, Barraco Daniela, Lasho Terra L, Shah Sahrish, Begna Kebede H, Al-Kali Aref, Hogan William J, Litzow Mark R, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Pardanani Animesh

Abstract excerpt

One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Follow-Up Studies

Share to Janus Kinase 2

Share to Primary Myelofibrosis

Share to Pyrimidines

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 29515114
DOI: 10.1038/s41408-018-0067-6
PMCID: PMC5841331

Genes

ASXL1
CALR
SRSF2
JAK1
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Momelotinib therapy for myelofibrosis: a 7-year follow-up.PMID 29515114Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisSemantic proximity Read ↗

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.Semantic proximity Read ↗

Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.